VY 1706
Alternative Names: tau silencing gene therapy program; VY-1706Latest Information Update: 10 Apr 2025
At a glance
- Originator Voyager Therapeutics
- Class Antidementias; Gene therapies; Small interfering RNA
- Mechanism of Action RNA interference; Tau protein expression inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Alzheimer's disease
Most Recent Events
- 31 Mar 2025 Voyager Therapeutics plans to file a Clinical Trial Application (CTA) to the Health Canada for Alzheimer's disease, in 2026
- 31 Mar 2025 Voyager Therapeutics plans to file an IND application to US FDA for Alzheimer's disease, in 2026
- 31 Mar 2025 Safety, pharmacokinetics and pharmacodynamics data from preclinical studies in Alzheimer’s disease released by Voyager Therapeutics